Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4794 Target Snapshot

Transient receptor potential cation channel subfamily V member 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,675Compounds
649Assays
6Approved Drugs
6,492.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Transient receptor potential cation channel subfamily V member 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q8NER1. Start with pain, then reuse UniProt Q8NER1 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with pain, then reuse UniProt Q8NER1 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
pain

Transient receptor potential cation channel subfamily V member 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with pain because it currently carries approved-linked support. Linked drugs include ACETAMINOPHEN, AZD1386, CAPSAICIN, NGD-8243. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Transient receptor potential cation channel subfamily V member 1 as ChEMBL target CHEMBL4794, mapped to UniProt Q8NER1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Transient receptor potential cation channel subfamily V member 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4794
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8NER1
Transient receptor potential cation channel subfamily V member 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Transient receptor potential cation channel subfamily V member 1 is the right protein anchor across sources, using UniProt Q8NER1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why pain is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTransient receptor potential cation channel subfamily V member 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ8NER1
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTransient receptor potential cation channel subfamily V member 1
UniProt AccessionQ8NER1
Component TypeProtein
Sequence Length839 aa

Transient receptor potential cation channel subfamily V member 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Transient receptor potential cation channel subfamily V member 1, mapped to UniProt Q8NER1. Sequence length is 839 aa.

Mapped IDQ8NER1
Review nameTransient receptor potential cation channel subfamily V member 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Transient receptor potential cation channel subfamily V member 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
pain
6 linked drugs · 6 direct · 6 efficacy
Linked drugACETAMINOPHEN
Linked drugAZD1386
Linked drugCAPSAICIN
Linked drugNGD-8243
Approved-linked Approved
migraine disorder
3 linked drugs · 3 direct · 3 efficacy
Linked drugACETAMINOPHEN
Linked drugCAPSAICIN
Linked drugSB-705498
Approved-linked Approved
neuropathic pain
3 linked drugs · 3 direct · 3 efficacy
Linked drugACETAMINOPHEN
Linked drugAZD1386
Linked drugCAPSAICIN
Approved-linked Approved
Arthralgia
2 linked drugs · 2 direct · 2 efficacy
Linked drugCAPSAICIN
Linked drugZUCAPSAICIN
Approved-linked Approved
arthritis
2 linked drugs · 2 direct · 2 efficacy
Linked drugACETAMINOPHEN
Linked drugCAPSAICIN
Approved-linked Approved
Back pain
2 linked drugs · 2 direct · 2 efficacy
Linked drugACETAMINOPHEN
Linked drugCAPSAICIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with pain because it currently carries approved-linked support. Linked drugs include ACETAMINOPHEN, AZD1386, CAPSAICIN, NGD-8243. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepain
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
7
Phase III
14
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC504,628.0
KI1,178.0
EC50675.0
KD11.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2177429 11.0 Ki 0.01 Preclinical
CHEMBL17976 10.72 EC50 0.019 Clinical
CHEMBL3407762 10.7 Ki 0.02 Preclinical
CHEMBL2177428 10.7 Ki 0.02 Preclinical
CHEMBL3393837 10.7 Ki 0.02 Preclinical
CHEMBL3627950 10.52 Ki 0.03 Preclinical
CHEMBL3627723 10.52 Ki 0.03 Preclinical
CHEMBL3407765 10.4 Ki 0.04 Preclinical
CHEMBL3689037 10.4 Ki 0.04 Preclinical
CHEMBL2442912 10.3 Ki 0.05 Preclinical
Distribution

pChEMBL Value Distribution

263
5.0
400
5.5
646
6.0
778
6.5
1012
7.0
768
7.5
588
8.0
336
8.5
245
9.0
84
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPSAICIN
CHEMBL294199
Approved 2009
Properties Compare Identifier
PROPOFOL
CHEMBL526
Approved 1989
Properties Compare Identifier
Assay Landscape

Assay Landscape

650
Total Assays
3,038
Tested Compounds
3
Assay Types
Binding — 482 assays, 3,038 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 341 2,211 7.2
single protein format 107 223 6.9
assay format 21 604 7.1
organism-based format 13 0 —
Functional — 166 assays, 1,142 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 124 822 7.1
assay format 41 319 7.3
tissue-based format 1 1 9.3
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine